Please Wait.....
Report
Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market - Industry Trends and Forecast to 2031
Market Report I 2023-12-01 I 138 Pages I Data Bridge Market Research
The Indonesia, Malaysia, Thailand, Phillipnes, and Vietnam IgA nephropathy market is expected to reach USD 42,340.41 thousand by 2034 from USD 15,716.44 thousand in 2023, growing with a CAGR of 10.1% in the forecast period of 2024 to 2034.
Market Segmentation
Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market, By Disease Type (Primary IgA Nephropathy and Secondary IgA Nephropathy), Type (Diagnosis and Treatment), Population Type (Adults, Geriatric, and Pediatric), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Ambulatory Care Centers, Home Healthcare, and Others), Distribution Channel (Retail Sales, Direct Tenders, and Others), Country (Indonesia, Malaysia, Thailand, Philippines, and Vietnam) - Industry Trends and Forecast to 2034
Overview of Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Dynamics:
Driver
- Rise in the number of IgA nephropathy cases
Restraint
- High cost of IgA nephropathy treatment
Opportunity
- Collaboration among market players for drug development
Market Players
Some of the major market players operating in the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market are:
- Sun Pharmaceutical Industries Ltd
- Pfizer Inc.
- Zydus Group
- Novartis AG
- ARKRAY USA, Inc.
- Teva Pharmaceutical USA Inc.
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF INDONESIA, MALAYSIA, THAILAND, PHILIPPINES & VIETNAM IGA NEPHROPATHY MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 20
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 YEARS CONSIDERED FOR THE STUDY 23
2.3 CURRENCY AND PRICING 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 MULTIVARIATE MODELLING 27
2.6 DBMR MARKET POSITION GRID 29
2.7 VENDOR SHARE ANALYSIS 30
2.8 SECONDARY SOURCES 31
2.9 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHT 34
4.1 PESTEL ANALYSIS 35
4.2 PORTER'S FIVE FORCES 36
4.3 PREVALENCE OF IGA NEPHROPATHY 37
4.4 INCIDENCE OF IGA NEPHROPATHY 37
4.5 CURRENT TREATMENT OF IGA NEPHROPATHY 37
4.6 EXPENDITURE OF IGA NEPHROPATHY 37
4.7 DETECTION METHODS OF IGA NEPHROPATHY 38
5 MARKET OVERVIEW 40
5.1 DRIVERS 42
5.1.1 RISE IN THE NUMBER OF CASES OF IGA NEPHROPATHY 42
5.1.2 INCREASE IN THE AVAILABILITY OF IGA-TARGETED PIPELINE DRUGS 42
5.1.3 INCREASING INVESTMENT IN R&D OF DRUG DISCOVERY 42
5.1.4 INCREASING PRODUCT APPROVALS FOR IGA NEPHROPATHY TREATMENT 43
5.2 RESTRAINTS 43
5.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT 43
5.2.2 DELAYED DIAGNOSIS OF IGA NEPHROPATHY 44
5.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES 44
5.2.4 INABILITY TO EFFECTIVELY TREAT IGA NEPHROPATHY 44
5.3 OPPORTUNITIES 45
5.3.1 COLLABORATION AMONG MARKET PLAYERS FOR DRUG DEVELOPMENT 45
5.3.2 INCREASE IN GOVERNMENT FUNDING FOR RESEARCH PURPOSES 45
5.3.3 INCREASING TREND OF NOVEL DIAGNOSIS PROCEDURE 46
5.4 CHALLENGES 46
5.4.1 LOW AWARENESS AMONG THE POPULATION REGARDING KIDNEY DISEASE 46
5.4.2 STRINGENT GOVERNMENT REGULATIONS RELATED TO THE APPROVAL OF NEUROENDOCRINE TUMOR DRUG 47
6 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISEASE TYPE 48
6.1 OVERVIEW 49
6.2 PRIMARY IGA NEPHROPATHY 52
6.3 SECONDARY IGA NEPHROPATHY 52
7 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY TYPE 53
7.1 OVERVIEW 54
7.2 DIAGNOSIS 57
7.2.1 URINE TEST 57
7.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO 57
7.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD 58
7.2.2 BLOOD TEST 58
7.2.3 IOTHALAMATE CLEARANCE TEST 58
7.2.4 KIDNEY BIOPSY 58
7.2.5 OTHERS 58
7.3 TREATMENT 58
7.3.1 BLOOD PRESSURE LOWERING AGENTS 59
7.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 59
7.3.1.1.1 LISINOPRIL 59
7.3.1.1.2 ENALAPRIL 60
7.3.1.1.3 RAMIPRIL 60
7.3.1.1.4 BENAZEPRIL 60
7.3.1.1.5 OTHERS 60
7.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERs 60
7.3.1.2.1 LOSARTAN 60
7.3.1.2.2 VALSARTAN 61
7.3.1.2.3 IRBESARTAN 61
7.3.1.2.4 OTHERS 61
7.3.2 IMMUNOSUPPRESANT 61
7.3.2.1 CYCLOPHOSPHAMIDE 61
7.3.2.2 AZATHIOPRINE 61
7.3.2.3 CORTICOSTEROIDS 61
7.3.2.3.1 METHYLPREDNISONE 62
7.3.2.3.2 PREDNISOLONE 62
7.3.2.3.3 OTHERS 62
7.3.2.4 OTHERS 62
7.3.3 DIURETICS 63
7.3.3.1 FUROSEMIDE 63
7.3.3.2 TORSEMIDE 63
7.3.3.3 BUMETANIDE 63
7.3.3.4 OTHERS 63
7.3.4 BLOOD CHOLESTEROL LOWERING AGENTS 63
7.3.4.1 ATROVASTATIN 64
7.3.4.2 SIMVASTATIN 64
7.3.4.3 ROSUVASTATIN 64
7.3.4.4 FLUVASTATIN 64
7.3.4.5 PRAVASTATIN 64
7.3.4.6 OTHERS 64
7.3.5 SUPPLEMENTS 65
7.3.5.1 OMEGA-3-FATTY ACIDS 65
7.3.5.2 VITAMIN E 65
7.3.5.3 OTHERS 65
7.3.6 OTHERS 65
8 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY POPULATION TYPE 66
8.1 OVERVIEW 67
8.2 ADULTS 70
8.3 GERIATRIC 70
8.4 PEDIATRIC 70
9 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION 71
9.1 OVERVIEW 72
9.2 ORAL 75
9.2.1 TABLETS/PILLS 75
9.2.2 CAPSULES 75
9.2.3 OTHERS 75
9.3 PARENTERAL 76
9.3.1 INTRAVENOUS 76
9.3.2 SUBCUTANEOUS 76
9.3.3 OTHERS 76
9.4 OTHERS 76
10 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY END USER 77
10.1 OVERVIEW 78
10.2 HOSPITALS 81
10.2.1 PRIVATE 81
10.2.2 PUBLIC 81
10.3 SPECIALTY CLINICS 81
10.4 DIAGNOSTIC CENTERS 81
10.5 AMBULATORY CARE CENTERS 81
10.6 HOME HEALTHCARE 82
10.7 OTHERS 82
11 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL 83
11.1 OVERVIEW 84
11.2 RETAIL SALES 87
11.2.1 HOSPITAL PHARMACY 87
11.2.2 ONLINE PHARMACY 87
11.2.3 RETAIL PHARMACY 87
11.3 DIRECT TENDER 87
11.4 OTHERS 87
12 INDONESIA, MALAYSIA, PHILIPPINES, THAILAND AND VIETNAM 88
12.1 MALAYSIA 89
12.2 THAILAND 95
12.3 INDONESIA 101
12.4 PHILIPPINES 107
12.5 VIETNAM 113
13 INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND IGA NEPHROPATHY MARKET, COMPANY LANDSCAPE 119
13.1 COMPANY SHARE ANALYSIS: INDONESIA, MALAYSIA, PHILIPPINES, VIETNAM, AND THAILAND 119
14 SWOT ANALYSIS 120
15 COMPANY PROFILE 121
15.1 SUN PHARMACEUTICAL INDUSTRIES LTD 121
15.1.1 COMPANY SNAPSHOT 121
15.1.2 REVENUE ANALYSIS 122
15.1.3 PRODUCT PORTFOLIO 122
15.1.4 RECENT DEVELOPMENTS 123
15.3 PFIZER INC. 124
15.3.1 COMPANY SNAPSHOT 124
15.3.2 REVENUE ANALYSIS 124
15.3.3 PRODUCT PORTFOLIO 125
15.3.4 RECENT DEVELOPMENT 125
15.4 ZYDUS GROUP. 126
15.4.1 COMPANY SNAPSHOT 126
15.4.2 REVENUE ANALYSIS 126
15.4.3 PRODUCT PORTFOLIO 127
15.4.4 RECENT DEVELOPMENTS 127
15.5 NOVARTIS AG 128
15.5.1 COMPANY SNAPSHOT 128
15.5.2 REVENUE ANALYSIS 128
15.5.3 PRODUCT PORTFOLIO 129
15.5.4 RECENT DEVELOPMENTS 129
15.6 ARKRAY USA, INC. 131
15.6.1 COMPANY SNAPSHOT 131
15.6.2 PRODUCT PORTFOLIO 131
15.6.3 RECENT DEVELOPMENTS 131
15.7 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 132
15.7.1 COMPANY SNAPSHOT 132
15.7.2 REVENUE FINANCIALS 132
15.7.3 PRODUCT PORTFOLIO 133
15.7.4 RECENT DEVELOPMENTS 133
16 QUESTIONNAIRE 135
17 RELATED REPORTS 138
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security